Johnson & Johnson Publishes Results of COVID-19 Single Shot Vaccine in NEJM
Shots:
- The P-III ENSEMBLE trial involves assessing COVID-19 vaccine vs PBO in 43-783 enrolled participants aged ≥18yrs. with both mod. and sev. COVID-19 disease
- The trial met all 1EP & 2EPs i.e 85% efficacy in preventing disease- vaccine efficacy was consistent against symptomatic infection including in South Africa and Brazil that showed a high prevalence of SARS-CoV-2 variants
- Additionally- the trial met its co-1EPs of protecting against mod. to sev. COVID-19 that showed 67% efficacy @14days and 66 % efficacy @28days after vaccination. The vaccine demonstrated efficacy as early as 7days after vaccination- with efficacy continuing to increase 8wks. post-vaccination
Ref: J&J | Image: Market Watch
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com